Study on c-Met Targeted PET/CT Imaging in NSCLC

In the study, NSCLC patients with different c-Met activation status (c-Met overexpression, MET exon 14 skipping mutation, MET amplification, MET wild type) confirmed by pathology or gene detection will receive 18F-TSPF PET/CT and 18F-FDG PET/CT respectively. The goal of the study is to evaluate specificity and accuracy of 18F-TSPF as a novel PET radiotracer to detect c-Met activation status and potentially identify c-Met-TKIs benefited NSCLC patients.

Inclusion criteria

• Age range 18-75 years, open to both male and female participants;
• Normal hepatic/renal function and cardiac function;
• Expected survival of at least 12 weeks;
• Good adherence to follow-up;
• Presence of at least one measurable target lesion according to RECIST 1.1 criteria;
• Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;
• Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;
• Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.

Exclusion criteria

• Severe abnormalities in liver and renal function and blood counts;
• Patients planning to conceive;
• Pregnant or lactating women;
• Individuals unable to lie flat for thirty minutes;
• Individuals who refuse to participate in this clinical study;
• Individuals suffering from claustrophobia or other psychiatric disorders;
• Other situations deemed unsuitable for trial participation by the researchers.